Known targets — ChEMBL curated mechanism
GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ
The experimentally established mechanism targets of Lorazepam. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP known ✓ | O00591 | 1/20 | 0.58 |
| ▸ | GABRD known ✓ | O14764 | 1/20 | 0.58 |
| ▸ | GABRA1 known ✓ | P14867 | 1/20 | 0.58 |
| ▸ | GABRB1 known ✓ | P18505 | 1/20 | 0.58 |
| ▸ | GABRG2 known ✓ | P18507 | 1/20 | 0.58 |
| ▸ | GABRB3 known ✓ | P28472 | 1/20 | 0.58 |
| ▸ | GABRA5 known ✓ | P31644 | 1/20 | 0.58 |
| ▸ | GABRA3 known ✓ | P34903 | 1/20 | 0.58 |
| ▸ | GABRA2 known ✓ | P47869 | 1/20 | 0.58 |
| ▸ | GABRB2 known ✓ | P47870 | 1/20 | 0.58 |
| ▸ | GABRA4 known ✓ | P48169 | 1/20 | 0.58 |
| ▸ | GABRE known ✓ | P78334 | 1/20 | 0.58 |
| ▸ | GABRA6 known ✓ | Q16445 | 1/20 | 0.58 |
| ▸ | GABRG1 known ✓ | Q8N1C3 | 1/20 | 0.58 |
| ▸ | GABRG3 known ✓ | Q99928 | 1/20 | 0.58 |
| ▸ | GABRQ known ✓ | Q9UN88 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 0.75 |
| ▸ | ALB | P02768 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lorazepam SCHEMBL5271784 | 1.00 | LMNA (1.00) | LMNAPGRMEN1ALBKMT2A | |
| Lorazepam SCHEMBL29516559 | 1.00 | LMNA (1.00) | LMNAPGRMEN1ALBKMT2A | |
| (R)-Lorazepam SCHEMBL26962 | 1.00 | LMNA (1.00) | LMNAPGRMEN1ALBKMT2A | |
| Lorazepam SCHEMBL29388543 | 1.00 | LMNA (1.00) | LMNAPGRMEN1ALBKMT2A | |
| Lorazepam SCHEMBL29358033 | 1.00 | LMNA (1.00) | LMNAPGRMEN1ALBKMT2A | |
| (S)-Lorazepam SCHEMBL120031 | 1.00 | LMNA (1.00) | LMNAPGRMEN1ALBKMT2A | |
| Lorazepam SCHEMBL26961 | 1.00 | LMNA (1.00) | LMNAPGRMEN1ALBKMT2A | |
| Lorazepam SCHEMBL28931472 | 0.99 | LMNA (0.97) | LMNAPGRMEN1ALBKMT2A | |
| Lorazepam SCHEMBL5908139 | 0.99 | LMNA (0.97) | LMNAPGRMEN1ALBKMT2A | |
| Lorazepam SCHEMBL6500339 | 0.99 | LMNA (0.97) | LMNAPGRMEN1ALBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090208413-A1 | Registry Method and Control System for Dea Schedule II-V Medicines | DR PHARMA NOVA, LLC | 2009-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090208413-A1 | Registry Method and Control System for Dea Schedule II-V Medicines | DUT, CNR2, QDPR | GABRP 2405/4885GABRD 715/4885GABRA1 1781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.